Protalix BioTherapeutics, Inc.
PLX evidence brief
What we can confirm
- BioSniper Score:
- 8.7 / 10
- Market Cap:
- $212.7M
- Lead Asset:
- elelyso (Approved)
What it means
What to watch
Prepared research question
What matters most for PLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLX
Protalix BioTherapeutics (PLX) is a biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins for rare and orphan diseases, leveraging its proprietary ProCellEx protein expression platform.
Key risk: Financing risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates for Protalix BioTherapeutics, Inc..
Protalix BioTherapeutics (PLX) is a biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins for rare and orphan diseases, leveraging its proprietary ProCellEx protein expression platform.
- As of 2026-06-30, Protalix reported cash & equivalents of $27.4M, total revenue of $19.9M, net income of $3.8M, and shareholders' equity of $71.4M [sec].
- Elfabrio (pegunigalsidase alfa) for Fabry disease is approved in the U.S., EU, and other jurisdictions; in March 2026, a 2 mg/kg every-four-weeks dosage was approved in the EU [sec_mda · as of 2026-08-12].
- The company's pipeline includes PRX-115 (PEGylated Uricase for uncontrolled gout, Phase I completed) and PRX-119 (Long Acting DNase I, preclinical), with a RELEASE study ongoing [sec_mda · as of 2026-03-18].
- Protalix sells Elelyso drug substance to Pfizer and Fiocruz at fixed prices, with revenue recognized upon delivery; orders can vary period-to-period and may not directly reflect patient demand [sec_mda · as of 2025-11-13].
- The company expects to continue incurring significant R&D expenditures and may need additional financing, noting that stock price volatility could make fundraising difficult [sec_mda · as of 2026-08-12].
What works
- Elfabrio has secured regulatory approvals in multiple major markets (U.S., EU) and recently expanded its approved dosing option in the EU, potentially broadening patient access [sec_mda · as of 2026-08-12].
- Protalix has a proprietary ProCellEx protein expression platform that it continues to enhance, providing a foundation for developing new product candidates [sec_mda · as of 2026-08-12].
- The company reported positive net income ($3.8M) as of 2026-06-30, indicating a period of profitability [sec].
What to weigh
- Revenue from Elfabrio and Elelyso may not be sufficient to fund ongoing R&D expenditures, and the company acknowledges difficulty in obtaining additional financing due to stock price volatility [sec_mda · as of 2026-08-12].
- The company faces inherent clinical and regulatory risks, including the possibility that clinical trials may not support safety/efficacy claims or that regulatory authorities may not approve marketing applications [sec_mda · as of 2026-05-13].
- Sales of Elelyso to Pfizer and Fiocruz are subject to order variability and inventory de-stocking, which can cause period-to-period revenue fluctuations not tied to patient demand [sec_mda · as of 2025-11-13].
From the filings
Quoted directly from source documents.
Elfabrio approved in EU for 2 mg/kg every-four-weeks dosage in March 2026
“in March 2026, Elfabrio was approved for a 2 mg/kg every-four-weeks (E4W) dosage in the European Union.”
SEC MD&A · August 12, 2026
Protalix expects to continue incurring significant R&D expenditures and may need additional financing
“As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures.”
SEC MD&A · August 12, 2026
Sales of Elelyso to Pfizer and Fiocruz are at fixed price and recognized upon delivery, with order variability
“We sell the products at a fixed price directly to Pfizer and Fiocruz who maintain product in inventory, and we recognize revenue from those sales upon delivery. The timing of such sales does not directly reflect patient demand and, on a period-to-period basis, there may be variations in the orders placed by each of Pfizer and Fiocruz resulting in variability in our period-to-period results.”
SEC MD&A · November 13, 2025
Risks & what to watch (3)›
Key risks
- Financing risk — Revenues may not cover R&D costs; stock price volatility may hinder raising additional capital [sec_mda · as of 2026-08-12].
- Clinical/regulatory failure — Clinical trials may not support safety/efficacy; regulators may not approve marketing applications [sec_mda · as of 2026-05-13].
- Revenue variability — Elelyso sales to Pfizer/Fiocruz are subject to order timing and inventory de-stocking, causing period-to-period fluctuations [sec_mda · as of 2025-11-13].
What to watch
- Completion of enrollment in the RELEASE study for PRX-115 (PEGylated Uricase) [sec_mda · as of 2026-03-18].
- Progress of PRX-119 (Long Acting DNase I) through IND-enabling studies [sec_mda · as of 2026-03-18].
- Commercial uptake of Elfabrio, particularly the new E4W dosing option approved in the EU in March 2026 [sec_mda · as of 2026-08-12].
- Any changes in ordering patterns from Pfizer and Fiocruz for Elelyso, which affect revenue stability [sec_mda · as of 2025-11-13].
Sources: SEC filings · SEC MD&A · Generated September 26, 2026 · How we verify sources →
Run Protalix BioTherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Protalix BioTherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.55 · 3% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
99
Total value held
$35.8M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 3,616,962 | $7.8M |
| mak capital one llc | 3,544,139 | $7.7M |
| renaissance technologies llc | 1,224,800 | $2.7M |
| state street corp | 972,815 | $2.1M |
| northern trust corp | 885,448 | $1.9M |
| geode capital management, llc | 865,298 | $1.9M |
| stratos wealth partners, ltd. | 500,000 | $1.1M |
| vanguard portfolio management llc | 432,485 | $938K |
| prospera financial services inc | 418,570 | $908K |
| opaleye management inc. | 340,000 | $738K |
Showing top 10 of 99 institutional holders of Protalix BioTherapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 29, 2026- % of float
- 6.1%
- Days to cover
- 4.8
- Shares short
- 4,726,273
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Protalix BioTherapeutics, Inc.?
Protalix BioTherapeutics (PLX) is a biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins for rare and orphan diseases, leveraging its proprietary ProCellEx protein expression platform.
What is Protalix BioTherapeutics, Inc.'s lead drug candidate?
Protalix BioTherapeutics, Inc.'s most advanced tracked candidate is elelyso (Approved) for Gaucher disease.
Who is the CEO of Protalix BioTherapeutics, Inc.?
Mr. Dror Bashan is the chief executive officer of Protalix BioTherapeutics, Inc. (PLX).
Where is Protalix BioTherapeutics, Inc. headquartered?
Protalix BioTherapeutics, Inc. (PLX) is headquartered in Hackensack, NJ, United States.
What therapeutic areas does Protalix BioTherapeutics, Inc. focus on?
Protalix BioTherapeutics, Inc. develops therapies across Rare Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.